Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Change in Cash (2016 - 2025)

Karyopharm Therapeutics' Change in Cash history spans 14 years, with the latest figure at $22.9 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 320.89% year-over-year to $22.9 million; the TTM value through Dec 2025 reached -$1.9 million, down 119.99%, while the annual FY2025 figure was -$1.9 million, 119.99% down from the prior year.
  • Change in Cash reached $22.9 million in Q4 2025 per KPTI's latest filing, up from -$1.1 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $63.8 million in Q4 2022 to a low of -$70.9 million in Q2 2022.
  • Average Change in Cash over 5 years is -$1.4 million, with a median of -$3.0 million recorded in 2021.
  • Peak YoY movement for Change in Cash: crashed 4917.55% in 2022, then surged 1554.22% in 2024.
  • A 5-year view of Change in Cash shows it stood at $57.0 million in 2021, then increased by 11.97% to $63.8 million in 2022, then tumbled by 86.51% to $8.6 million in 2023, then crashed by 220.23% to -$10.4 million in 2024, then surged by 320.89% to $22.9 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Change in Cash are $22.9 million (Q4 2025), -$1.1 million (Q3 2025), and -$48000.0 (Q2 2025).